Press releases
- ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
- GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium
- Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
Tweets from GSK US
-
GSKUS @GSKUS
#Cancer doesn’t stop because of a pandemic. Our own Michael Petroutsas RPh, SVP, US Oncology, discussed 4 ways the #COVID19 pandemic has changed #oncology for good, & how our teams quickly adapted to continue putting patients first. gsk.to/3o3pzix
about 3 days ago
-
GSKUS @GSKUS
#HCPs: Do your 50+ patients know that they are at risk of developing #shingles, even if they are healthy and active? Find resources to share with your patients on our #ShinglesDoesntPlayFavorites page: 👉gsk.to/3qt44tpd
about 3 days ago
Jj
-
GSKUS @GSKUS
On this national #MLKDayofService, our colleagues will part take in virtual volunteering projects across the country. What will you do to give back today?
about 4 days ago
